BEIJING (Reuters) – Sinovac Biotech’s COVID-19 vaccine appears to be safe and able to trigger immune responses among children and adolescents, according to preliminary results from early and mid-stage trials, the company said late on Monday.
The preliminary data was from Phase I and II clinical trials involving over 500 people between the ages of three and 17 who received two shots of either medium or low dosage of vaccine, or a placebo.
Most adverse reactions were mild, Zeng Gang, a researcher with the company, told an academic conference in Beijing.
Two children who received the lower dose were reported to have experienced higher fever, categorized as grade 3, he said, without providing details or specific temperature.
The antibody levels triggered by Sinovac’s CoronaVac were higher than those seen in adults aged 18 to 59 and in elderly people in earlier clinical trials, Zeng said in the presentation.
For children three to 11 years old, the lower dose could induce favorable antibody responses, and the medium dose worked well for those aged 12 to 17, he said.
The preliminary data has not yet been published in a peer-reviewed medical journal.
Sinovac’s overseas Phase III trials testing the vaccine’s ability to prevent COVID-19 disease have so far not included minors.
The company is also testing a third booster shot in a China-based clinical trial, with participants given a third dose around eight months after receiving the second.
Sinovac has supplied 160 million vaccine doses to 18 countries and regions including China, with over 70 million doses administered.
(Reporting by Rosanne Liu and Ryan Woo; Editing by Peter Henderson and Bill Berkrot)
